SynthesisLangenbeck's archives of surgery2025
Surgical management of longstanding overt ventriculomegaly in adults: evaluating the role of endoscopic third ventriculostomy.
Synthesis in Langenbeck's archives of surgery, 2025. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Not yet cited in PubMed.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
0 citing papers in PubMed.
No citing paper in PubMed yet.
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
8 authors.
Funding
No grant is acknowledged in the PubMed record.
Abstract
backgroundLongstanding Overt Ventriculomegaly in Adults (LOVA) and Obstructive Hydrocephalus (o-HCP) is the abnormal accumulation of cerebrospinal fluid (CSF), leading to increased intracranial pressure, and associated neurological symptoms. Endoscopic Third Ventriculostomy (ETV) is a minimally invasive surgical treatment for these conditions. ETV has demonstrated effectiveness in pediatric populations, its efficacy in adult patients remains ambigous. This systematic review and meta-analysis aims to evaluate the outcomes of ETV in adult patients with LOVA and o-HCP.
methodsA systematic review along with meta-analysis were carried out following the PRISMA guidelines. Studies were identified through PubMed, Cochrane, Scopus, and CINAHL databases using relevant MeSH terms and BOOLEAN operators. The inclusion criteria followed the PICO model, focusing on adult patients (> 18 years) undergoing ETV. Data on postoperative complications, symptom improvement, and successful treatment outcomes were extracted. Statistical analysis, including sensitivity analyses, was performed using R Studio, with odds ratios (OR) and heterogeneity (I²) calculated. The Newcastle-Ottawa Scale was employed to assess for risk of bias.
resultsA total of 8 studies comprising 200 patients were included. The overall odds ratio for successful treatment following ETV was 4.59 (95% CI: 2.74-7.67) with moderate heterogeneity (I² = 53%). Sensitivity analysis reduced the heterogeneity to 0%, increasing the OR to 5.56 (95% CI: 3.80-8.13). Significant improvements were noted in specific symptoms, including headache (OR 9.47, 95% CI: 4.31-20.81, I² = 0%), balance (OR 10.78, 95% CI: 4.00-29.03, I² = 35%), and memory (OR 6.64, 95% CI: 1.38-31.86, I² = 61%). A low risk of bias was observed across all studies included.
conclusionsETV is an effective treatment for patients with LOVA and o-HCP, demonstrating significant symptom improvement and a high success rate. Low heterogenicity of outcomes with robust findings confirmed sensitivity analyses. However, patient-specific factors, such as age and duration of symptoms, should be considered for ETV.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.